The mission of St. Jude Children's Research Hospital is to find cures for children with catastrophic illnesses through research and treatment. Founded by the late entertainer, Danny Thomas, the hospital opened in 1962. The resources of the hospital have been focused on pediatric cancer throughout its 39-year history. Supported by a CCSG for 24 years, St. Jude Children's Cancer Center is the only NCI funded Cancer Center dedicated exclusively to research and treatment of cancer in children. Mr. Thomas also founded the American Lebanese Syrian Associated Charities (ALSAC), a separate corporation whose only purpose is to raise money in support of St. Jude Children's Research Hospital. Patients are accepted without regard to race, religion or ability to pay. Any costs beyond that provided by third party payers are covered by ALSAC, allowing our research to be conceptually driven without the usual financial constraints on clinical investigation in the context of patient care. The Cancer Center is dedicated to long-term follow-up of its patients, thereby providing a framework for growing cancer prevention and control research initiatives which are encompassed within our research programs. Public support of the hospital through ALSAC provides an unusually strong foundation for our Cancer Center upon which extramurally funded research and CCSG support can be leveraged to their fullest potential. The St. Jude Children's Cancer Center has seven multidisciplinary research programs which collectively span the spectrum from discovery oriented research to clinical application with an emphasis on translation. Research by the 136 members of the Cancer Center is supported by 17 Shared Resources, three of which have been developed during the last cycle and which we are now proposing for CCSG funding. The overall structure of our Cancer Center and its leadership, enhanced by the recruitment of three additional, strong scientific leaders, has otherwise remained very stable. New or rapidly growing research initiatives include Developmental Neurobiology, Structural Biology, Bioinformatics and Biotechnology. Our extramural support for cancer research has nearly doubled from $21.3 million in 1996 to over $40 million today. Planned future initiatives include Chemical Biology and expansion of Immunology. In summary, our Cancer Center has grown substantially and been greatly strengthened during the past five years through recruitment, maturation of our programs and development of new research initiatives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-26
Application #
6620456
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1977-09-01
Project End
2007-02-28
Budget Start
2003-03-01
Budget End
2004-02-29
Support Year
26
Fiscal Year
2003
Total Cost
$4,758,536
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Stewart, Elizabeth; McEvoy, Justina; Wang, Hong et al. (2018) Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell 34:411-426.e19
Broniscer, Alberto; Hwang, Scott N; Chamdine, Omar et al. (2018) Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts. Brain Pathol 28:112-120
Wogksch, Matthew D; Howell, Carrie R; Wilson, Carmen L et al. (2018) Physical fitness in survivors of childhood Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort. Pediatr Blood Cancer :e27506
Nishii, Rina; Moriyama, Takaya; Janke, Laura J et al. (2018) Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood 131:2466-2474
Fernandez-Pineda, Israel; Davidoff, Andrew M; Lu, Lu et al. (2018) Impact of ovarian transposition before pelvic irradiation on ovarian function among long-term survivors of childhood Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer 65:e27232
Vanarotti, Murugendra; Evison, Benjamin J; Actis, Marcelo L et al. (2018) Small-molecules that bind to the ubiquitin-binding motif of REV1 inhibit REV1 interaction with K164-monoubiquitinated PCNA and suppress DNA damage tolerance. Bioorg Med Chem 26:2345-2353
Quinn, Melissa; Fannin, J T; Sciasci, Joseph et al. (2018) Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy. Antimicrob Agents Chemother 62:
Halalsheh, Hadeel; Kaste, Sue C; Navid, Fariba et al. (2018) The role of routine imaging in pediatric cutaneous melanoma. Pediatr Blood Cancer 65:e27412
Wang, Lu; Hiler, Daniel; Xu, Beisi et al. (2018) Retinal Cell Type DNA Methylation and Histone Modifications Predict Reprogramming Efficiency and Retinogenesis in 3D Organoid Cultures. Cell Rep 22:2601-2614
Wang, Xusheng; Jones, Drew R; Shaw, Timothy I et al. (2018) Target-Decoy-Based False Discovery Rate Estimation for Large-Scale Metabolite Identification. J Proteome Res 17:2328-2334

Showing the most recent 10 out of 6764 publications